Medifast (NYSE:MED) Updates FY 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of -1.750–0.250 for the period, compared to the consensus EPS estimate of -1.870. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $281.0 million. Medifast also updated its Q3 2026 guidance to -0.650–0.150 EPS.

Medifast Stock Down 1.1%

Medifast stock traded down $0.10 during trading hours on Monday, reaching $9.72. 237,876 shares of the company’s stock were exchanged, compared to its average volume of 234,604. The firm’s 50 day simple moving average is $11.11 and its 200 day simple moving average is $11.05. Medifast has a twelve month low of $9.22 and a twelve month high of $15.11. The firm has a market capitalization of $108.14 million, a PE ratio of -5.31 and a beta of 0.65.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.The company had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Analysts anticipate that Medifast will post -1.97 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on MED. Zacks Research raised Medifast from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Weiss Ratings lowered shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.00.

Insider Activity

In other news, Director Scott Schlackman bought 2,500 shares of Medifast stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the purchase, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. This represents a 8.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Medifast by 30.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after acquiring an additional 181,618 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Medifast by 14.2% in the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock worth $6,186,000 after purchasing an additional 56,174 shares in the last quarter. Lido Advisors LLC bought a new position in shares of Medifast in the 3rd quarter worth $4,521,000. Dimensional Fund Advisors LP grew its position in Medifast by 9.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer’s stock valued at $3,484,000 after purchasing an additional 27,871 shares during the period. Finally, Steamboat Capital Partners LLC acquired a new stake in Medifast in the 4th quarter valued at $2,952,000. Institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.